Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort

•Research on homogeneous, isocitrate dehydrogenase-mutant, and 1p/19q-codeleted cohorts of oligodendrogliomas remains sparse.•For WHO grade 2 oligodendrogliomas, progression-free survival was prolonged after subtotal or gross total resection as well as treatment with chemotherapy or radiotherapy.•Herein, only a combined radiochemotherapy was associated with improved progression-free survival in patients suffering from WHO grade 3 oligodendrogliomas.